Health
FDA approves first personalized cell therapy for multiple myeloma – STAT
The therapy, developed by Bristol Myers Squibb and Bluebird Bio, will be marketed under the brand name Abecma.
The Food and Drug Administration on Friday approved the first personalized cell therapy to treat patients with advanced multiple myeloma. It will be marketed under the brand name Abecma by its makers, Bristol Myers Squibb and Bluebird Bio.
Multiple myeloma is a cancer that forms in plasma cells, a type of white blood cell that helps fight infections. In people with multiple myeloma, malignant plasma cells accumulate in the bone marrow, where they crowd out healthy blood cells, causing tumors, kidney…
Continue Reading
